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Background: Ingestion of polyunsaturated fatty acids (PUFAs) has been proposed to influence several chronic diseases
including coronary heart disease (CHD) and type-2 diabetes (T2D).There is strong evidence that omega-3 (n-3) PUFAs
provide protection against CHD and biomarkers of atherosclerosis. In contrast, there is more limited and inconsistent
data for T2D. Few studies have examined the impact of n-3 PUFA-containing botanical oils on T2D.
Methods: Fifty-nine subjects with early-stageT2D or metabolic syndrome participated in an 8-week, randomized,
single-blind, parallel intervention study and were provided PUFA-containing oils. Individuals received either corn oil
(CO), a botanical oil (BO) combination (borage [Borago officinalis L.]/echium oil [Echium plantagineum L.]) or fish oil
(FO). The BO combination was enriched in alpha-linolenic, gamma-linolenic, and stearidonic acids and the FO in
eicosapentaenoic and docosahexaenoic acids. Serum fatty acids and other serum lipids(triglycerides and total, HDL
and LDL cholesterol), as well as markers of inflammation (leptin, and C-reactive protein) and glucose regulation
(glucose and hemoglobin A1c) were assessed from fasting participants at baseline and after the intervention.
Results: Compliance was verified by expected increases in specific PUFAs in each of the three oil arms. Participants in
the CO group showed no differences in serum lipids, markers of inflammation or glucose regulation between pre- and
post-treatment measures. Supplementation with BO significantly lowered total and LDL cholesterol levels and FO
reduced serum triglycerides, hemoglobin A1c and increased HDL-cholesterol.
Conclusion: Short-term dietary supplementation with BO and FO improved biomarkers associated with T2D/metabolic
syndrome.
Trial registration: Clinicaltrial.gov NCT01145066
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Type 2 diabetes (T2D) is a major health concern in the
United States with an estimated 18.3 million adults having
physician-diagnosed diabetes, an additional 7.1 million
adults having undiagnosed diabetes and about 81.5 million
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unless otherwise stated.[1].The growing prevalence of obesity is strongly associ-
ated with low-grade systemic inflammation, dyslipidemia,
insulin resistance and diabetes, and lifestyle factors
including diet are known to play a critical role in the
development and progression of T2D [2-4].
Consumption of oily fish, enriched in n-3 long chain
polyunsaturated fatty acids (LcPUFAs) such as eicosa-
pentaenoic (EPA) and docosahexaenoic acid (DHA), has
long been observed to have health benefits [5,6]. For
example, consumption of these PUFAs has been shown
to be effective in decreasing the risk of cardiovascular
disease [7-10]. Based on these observations, it has beenis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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effects in T2D, glucose metabolism and insulin sensitivity.
However, several recent meta-analyses and prospective
studies [11-14] have revealed inconsistent results, and
some studies even suggest that elevated n-3 intake may in-
crease T2D in certain populations [15,16]. Randomized
clinical trials focused on the effects of PUFAs on the in-
cidence of diabetes have not been conducted. However,
several trials have examined whether T2D patients may
benefit from n-3 LcPUFA supplementation [17,18]; these
too showed conflicting results.
Inflammation is now thought to contribute to the de-
velopment of a variety of chronic diseases, including
T2D. There is a growing body of evidence in both hu-
man and animal studies that indicates that n-3 LcPUFAs
inhibit inflammation by altering the transcription of key
inflammatory genes and by competing with the n-6
LcPUFA, arachidonic acid (ARA), for key enzymes par-
ticipating in pro-inflammatory eicosanoid biosynthesis
(Figure 1) [19,20]. Additionally, n-3 LcPUFAs can be
converted to anti-inflammatory and pro-resolving mol-
ecules such as resolvins, protectins and n-3 derived
endocannabanoids [21].
In addition to n-3 marine oils, botanical oils can be
rich sources of n-6 and n-3 PUFAs. Figure 1 illustrates
the primary points where oil-derived PUFAs enter the
human PUFA biosynthetic pathway. Botanical oils have
been observed to possess anti-inflammatory properties.Figure 1 Primary points at which PUFA-based supplements enter the
proceeds in parallel pathways utilizing the same set of fatty acid desaturase
oils (Table 3) enter as both n-6 (LA, GLA) and n-3 (ALA, SDA, EPA, DPA, andBotanical oils such as borage and evening primrose were
initially shown to block cyclooxygenase and lipoxygenase
eicosanoid products and improve signs of rheumatoid
arthritis [22-25]. Gamma-linolenic acid (GLA; 18:3 n-6)
in evening primrose oil has also been shown to improve
the course of mild diabetic neuropathy [26]. It has been
shown that GLA is rapidly elongated to dihommo-GLA
(DGLA) in humans, and this product and its cyclooxy-
genase metabolite, prostaglandin E1, has been proposed
to attenuate inflammatory processes [24]. More recently,
we have demonstrated that botanical oils derived from
the seeds of the borage (Borago officinalis L.) and echium
(Echium plantagineum L.) plants administered to asth-
matic subjects effectively reduced the generation of pro-
inflammatory ARA metabolites by circulating immune
cells [27]. Borage oil, like evening primrose oil, is enriched
with GLA, and echium oil contains alpha-linolenic (ALA)
and stearidonic acids (SDA). We have also shown that this
botanical oil combination elevates circulating LcPUFAs
and improves glucose tolerance in insulin-resistant mon-
keys [28].
Together, these studies raise the question of whether
botanical oil-based dietary supplements could impact
T2D/metabolic syndrome in humans. Given the inconsist-
encies of the study designs and results derived from previ-
ously published studies with n-3 LcPUFAs and T2D and
the potential impact of botanical PUFAs on T2D, we de-
signed a randomized, single-blind, parallel interventionPUFA biosynthetic pathway. The biosynthesis of n-6 and n-3 PUFAs
(FADS) and elongase (ELOVL) enzymes. Components of the dietary
DHA) PUFAs.
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ments (corn oil, a botanical oil combination and fish oil)
on levels of serum fatty acids and other serum lipids (tri-
glycerides and total, HDL and LDL cholesterol), markers
of inflammation (leptin, and C-reactive protein), as well as
glucose regulation (glucose and hemoglobin A1c) in sub-
jects with early-stage T2D and metabolic syndrome.
Results
Characteristics of the patient population
Of the 80 participants entering the study, a total of 59
participants (74%) completed the study, with the remain-
der disqualifying (n = 9) or withdrawing (n = 12) for
health reasons. As outlined in Figure 2, 59 participants
were randomized to the three oil arms, receiving corn
oil (CO), a botanical oil (BO; a combination of echium
and borage oils), or fish oil (FO). The characteristics of
this study population are detailed in Table 1. The uniform-
ity of the baseline characteristics among the three arms
was assessed by ANOVA single variable analysis. No sig-
nificant differences in baseline characteristics among the
arms were observed as calculated by Chi-square analysis
or by One Way ANOVA.
Effect of supplementation on serum fatty acids
The effects of dietary supplementation with CO, BO and
FO on n-3 and n-6 PUFA levels are shown in Figure 3
and Table 2. Preliminary analyses demonstrated that the
impact of supplementation on all fasting PUFA levels
had stabilized by 4 weeks and did not change betweenFigure 2 Study design and randomization to intervention arms. Eighty T
parallel intervention study and 71 were randomized to the three intervention
withdrawals are shown for each arm.the 4- and 8-week time points (data not shown). Thus, the
data are expressed as baseline versus post-treatment sup-
plementation levels of PUFAs (mean of combined 4- and
8-week data). Since CO contains little or no n-3 PUFAs
(Table 3); it had no impact on circulating n-3 PUFA levels.
Linoleic acid (LA, 18:2n-6) is the primary PUFA in CO,
and there was a small increase in circulating LA levels
after CO supplementation (Figure 3B).
The BO provided alpha-linolenic acid (ALA, 18:3n-3)
and stearidonic acid (SDA, 18:4n-3) from echium oil
(Figure 1). Both of these PUFAs were significantly higher
in the BO arm after supplementation (Figure 3A, Table 2)
than at baseline. Eicosapentaenoic acid (EPA, 20:5n-3),
the elongation and desaturation product of ALA and SDA,
as well as EPA’s elongation product, docosapentaenoic acid
(DPA, 22:5n-3), also rose after supplementation with the
BO. However, there was no increase in circulating serum
docosahexaenoic acid (DHA, 22:6n-3). The borage oil
component of the BO supplement provided GLA (18:3n-6;
Table 3). This n-6 PUFA is metabolized to its elongation
and elongation/desaturation products, DGLA (20:3n-6) and
ARA (20:4n-6), respectively; both were significantly higher
after BO supplementation (Figure 3B).
As expected, FO supplementation induced a marked
increase in serum levels of n-3 LcPUFAs including EPA,
DPA and DHA. In contrast, FO also caused modest
reductions in n-6 PUFAs including GLA, DGLA and ARA
(Table 2). Overall, these data demonstrated that CO, BO
and FO supplementation produced changes in serum
PUFA levels that are consistent with the PUFA profile of2D or metabolic syndrome subjects were recruited into the double-blind,
arms. Fifty-nine subjects completed the study (74%). The reasons for
Table 1 Characteristics of the study population
Valuable Corn oil (CO) Botanical oil (BO)* Fish oil
n (%) n (%) n (%)
No. of subjects 21 (35.6) 22 (37.3) 16 (27.1)
Female 15 (71.4) 10 (45.5) 10 (62.5)
African American 6 (28.6) 8 (36.4) 7 (43.8)
Diabetic 14 (66.7) 18 (81.8) 13 (81.3)
Metabolic syndrome 7 (33.3) 4 (81.2) 3 (18.8)
Hypertensive 16 (76.2) 19 (86.4) 9 (56.3)
Mean (SD) Mean (SD) Mean (SD)
Age (years) 59.9 (9.8) 57.4 (7.8) 56.2 (8.7)
Weight (kg) 97.4 (17.2) 97.8 (18.7) 96.9 (15.1)
BMI (kg/m2) 34.8 (5.3) 34.1 (6.4) 33.2 (4.8)
Waist/hip ratio 0.9 (0.1) 0.9 (0.1) 0.9 (0.1)
Serum Glucose (mg/dl) 130.0 (44.9) 128.9 (50.8) 133.5 (64.7)
*BO arm received a combination of borage and echium oils.
p values were not significantly different between assignment groups, as calculated by Chi-square analysis of different proportions for each variable assigned to
each treatment group, nor by One Way ANOVA for morphometric values [mean (SD)].
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PUFAs in the supplements were clearly bioavailable and
entered the PUFA biosynthetic pathway. Furthermore, it
verifies that the subjects in each group were indeed com-
pliant with capsule consumption.
Effect of supplementation on disease biomarkers
The effects of dietary supplementation with CO, BO and
FO on the serum lipid (triglycerides and total, HDL and
LDL cholesterol) profile, markers of inflammation (leptin,
and C-reactive protein) and glucose regulation (glucose
and hemoglobin A1c) are shown in Table 4. Participants
receiving CO did not experience significant changes in
any of the disease biomarkers measured. In contrast,
participants receiving BO showed a significant decreaseFigure 3 Impact of dietary oil supplements on serum fatty PUFA prof
supplementation (black bar, combined 4- and 8-week data) for n-3 PUFAs
arm that reached statistical significance are indicated by *, p < 0.05 and **,in both total cholesterol (from 182.0 to 171.9 mg/dL;
p = 0.05) and LDL cholesterol (from 106.3 to 96.8 mg/dL;
p = 0.04). Participants receiving FO had significantly lower
levels of triglycerides (from 187.2 to 156.8 mg/dL;
p = 0.03), an increase in HDL-cholesterol (from 40.7 mg/dL
to 43.6 mg/dL; p = 0.01) and a significant increase in insulin
(from 19.1 μIU/mL to 24.6 μIU/mL; p = 0.02).
As of 2013, the American Diabetes Association (ADA)
criteria for the diagnosis of T2D included the presence
of any one of the following: 1) hemoglobin A1c ≥ 6.5%;
2) fasting plasma glucose ≥ 126 mg/dL; 3) 2 hour plasma
glucose ≥ 200 mg/dL following a 75 g oral glucose toler-
ance test; or 4) a random plasma glucose ≥ 200 mg/dL in a
patient with symptoms of hyperglycemia or a hypergly-
cemic crisis [29]. Participants in all three supplementationile. Data are the mean (SD) at baseline (white bar) and after oil
(A) and n-6 PUFAs (B). Pre – post changes within a supplementation
p <0.001.




Baseline* (SD) Post-oil* (SD) p-value Baseline* (SD) Post-oil* (SD) p-value Baseline* (SD) Post-oil* (SD) p-value
Cl4:0 0.70 (0.07) 0.66 (0.05) 0.56 0.69 (0.08) 0.66 (0.04) 0.86 0.72 (0.07) 0.62 (0.06) 0.78
C14:1 0 0 0 0 0 0
C15:0 0.15 (0.02) 0.14 (0.02) 0.58 0.13 (0.02) 0.14 (0.02) 0.46 0.16 (0.02) 0.14 (0.02) 0.38
C15:1 0 0 0 0 0 0
C16:0 21.19 (0.40) 20.75 (0.37) 0.23 20.64 (0.41) 20.49 (0.37) 0.71 21.65 (0.47) 20.76 (0.39) 0.51
C16:1 n-7 1.68 (0.13) 1.57 (0.13) 0.23 1.58 (0.08) 1.39 (0.08) 0.03 1.92 (0.24) 1.55 (0.14) 0.002
C17:1 0.08 (0.02) 0.04 (0.02) 0.24 0.10 (0.02) 0.05 (0.02) 0.05 0.13 (0.03) 0.06 (0.02) 0.05
C18:0 7.47 (0.09) 7.62 (0.12) 0.21 7.23 (0.14) 7.55 (0.16) <0.001 7.00 (0.25) 7.39 (0.27) 0.02
C18:1 0.21 (0.06) 0.25 (0.05) 0.21 0.12 (0.07) 0.13 (0.05) 0.63 0.17 (0.06) 0.25 (0.06) 0.02
C18:1 n-9 20.63 (0.96) 20.30 (0.61) 0.15 20.22 (0.51) 19.60 (0.44) 0.10 21.92 (0.98) 20.24 (0.52) 0.004
C18:1 n-11 1.60 (0.06) 1.51 (0.06) 0.03 1.50 (0.07) 1.44 (0.05) 0.94 1.84 (0.06) 1.56 (0.06) <0.001
C18:2 n-6 [LA] 31.99 (1.26) 33.11 (0.93) <0.001 32.67 (0.98) 30.97 (0.80) 0.002 29.71 (1.28) 29.94 (1.14) 0.86
C18:3 n-6 [GLA] 0.53 (0.03) 0.52 (0.03) 0.32 0.59 (0.04) 1.20 (0.08) <0.001 0.55 (0.05) 0.45 (0.05) 0.01
C18:3 n-3 [ALA] 0.73 (0.06) 0.71 (0.05) 0.85 0.80 (0.05) 1.05 (0.05) <0.001 0.77 (0.09) 0.83 (0.06) 0.16
C18:4 n-3 [SDA] 0.03 (0.02) 0.01 (0.00) 0.82 0.01 (0.01) 0.08 (0.01) 0.003 0.01 (0.01) 0.02 (0.01) 0.69
C20:0 0.01 (0.01) 0.01 (0.00) 0.81 0.00 (0.00) 0.00) (0.00) 1.00 0.00 (0.00) 0.00 (0.00) 1.00
C20:1 n-9 0.08 (0.02) 0.05 (0.01) 0.09 0.04 (0.01) 0.04 (0.01) 0.83 0.10 (0.02) 0.03 (0.01) 0.01
C20:2 n-6 0.30 (0.02) 0.31 (0.01) 0.72 0.32 (0.01) 0.24 (0.01) <0.001 0.33 (0.02) 0.23 (0.18) <0.001
C20:3 n-6 [DGLA] 1.68 (0.08) 1.61 (0.05) 0.32 1.51 (0.08) 1.97 (0.09) <0.001 1.43 (0.09) 1.45 (0.07) 0.002
C20:4 n-6 [AA] 8.17 (0.56) 8.11 (0.46) 0.83 9.12 (0.40) 9.16 (0.34) 0.05 8.68 (0.40) 7.31 (0.36) <0.001
C20:5 n-3 [EPA] 0.48 (0.04) 0.46 (0.05) 0.28 0.573 (0.05) 0.89 (0.08) <0.001 0.56 (0.07) 2.79 (0.18) <0.001
C22:0 0 0 0 0 0 0
C22:1 n-9 0.05 (0.04) 0.11 (0.04) 0.20 0.00 (0.00) 0.15 (0.06) 0.008 0.00 (0.00) 0.19 (0.11) 0.03
C22:2 n-6 0 0 0 0 0 0
C22:5 n-3 [DPA] 0.54 (0.03) 0.51 (0.03) 0.25 0.55 (0.02) 0.65 (0.02) <0.001 0.59 (0.03) 0.89 (0.03) <0.001
C24:0 0.02 (0.02) 0.02 (0.01) 0.81 0.02 (0.02) 0.01 (0.01) 0.88 0.00 (0.00) 0.01 (0.01) 1.00
C22:6 n-3 [DHA] 1.71 (0.12) 1.60 (0.11) 0.13 1.63 (0.10) 1.58 (0.11) 0.56 1.73 (0.016) 3.58 (0.11) <0.001
C24:1 n-9 0.03 (0.02) 0.01 (0.01) 0.25 0.01 (0.01) 0.00 (0.00) 0.50 0.04 (0.02) 0.00 (0.00) 0.25
*% total fatty acids.
Data are the mean (SD) at baseline and after oil supplementation (combined 4- and 8-week data). Pre – post changes within a supplementation arm that reached
statistical significance are shown by a bolded p-value.
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dL and an average hemoglobin A1c >6.5%. None of the oils
had any impact on fasting glucose levels. However, there
was a statistically significant reduction in hemoglobin A1c
in the FO arm (p = 0.05).
C-reactive protein (CRP) is a non-specific marker of
inflammation, but is often utilized as a tool in monitoring
patients with diabetes and heart disease [30,31]. Levels of
CRP were measured at baseline and again post-treatment.
Although none of the changes were statistically significant,
there was a trend toward reduction in CRP levels (from
6.08 to 3.59 mg/L; p = 0.19) in the FO arm. There were no
changes in any of the other disease biomarkers after sup-
plementation with any of the oils (Table 4).Discussion
To date, randomized controlled and prospective popula-
tion-based trials [32-35] that have assessed the impact of
n-3 PUFAs on T2D and insulin sensitivity have provided
inconsistent results regarding their effectiveness in pre-
venting or treating T2D. More recent studies suggests that
when an objective biomarker, such as levels of circulating
LcPUFAs, are used as a measure of exposure (as opposed
to dietary recall instruments), serum LcPUFAs are associ-
ated with long-term lower risk of T2D [36]. Given the
uncertainty around this question and the fact that a very
limited number of studies have examined the potential
impact of BO supplementation in humans, we carried out
a randomized, single blind, parallel intervention study to
Table 3 Fatty acid profile of the encapsulated oils and the daily dose of PUFAs consumed by each intervention arm
Fatty acid profile of dietary supplements (area%) PUFAs provided in dietary supplements by arm (g/day)
Common name Fatty acid Corn Borage Echium Fish CO BO* FO
Myristic C14:0 0 0 0 5.8
Palmitic C16:0 10.8 6.5 7.8 17.1
Palmitoleic C16:1 n-7 0 0 0.0 7.0
Stearic C18:0 2.8 3.3 5.0 4.1
Oleic C18:1 n-9 29.8 9.6 18.1 11.5
Vaccenic C18:1 n-11 0 0.4 0 3.0
Linoleic (LA) C18:2 n-6 54.2 22.1 18.6 1.9 3.96 1.80 0.48
Gamma-linoleic (GLA) C18:3 n-6 0 41.0 9.7 0.3 0 1.65 0.05
Alpha-linoleic (ALA) C18:3 n-3 0.8 0.2 28.0 1.2 0.06 1.90 0.23
Gondoic C20:1 n-9 0.2 5.6 0 0.5
Stearidonic (SDA) C18:4 n-3 0.1 0 12.2 4.5 <0.01 0.83 0.86
Dihommo-γ-linolenic (DGLA) C20:3 n-6 0 0 0 0.1
Behenic C22:0 0.1 0.3 0 1.3
Arachidonic (ARA) C20:4 n-6 0.2 0.1 0 0
Erucic C22:1 n-9 0 4.3 0.1 0
Eicosopentaenoic (EPA) C20:5 n-3 0.1 0 0 18.0 <0.01 0 3.58
Nervonic C24:1 n-9 0 3.2 0.1 0.9
Docosapentaenoic (DPA) C22:5 n-3 0 0 0 2.1
Docosahexaenoic (DHA) C22:6 n-3 0 0 0 12.3 0 0 2.44
Others 0.5 0.9 0 1.2
*BO arm received a combination of borage and echium oils.
The fatty acid composition of the oils was evaluated by gas chromatography. The PUFA doses were calculated based on the mass of oil in the number capsules
consumed daily, which were:9 CO capsules, 10 BO capsules (3 borage and 7 echium) or 9 FO capsules.
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ciated with T2D. Specifically, this study was designed
to examine the impact of CO, a BO combination (con-
taining borage and echium oil) or FO on biomarkers of
dyslipidemia, inflammation and glucose homeostasis.Table 4 Impact of dietary oil supplements on serum lipid pro
Arm CO
Variable Baseline (SD) Post-oil (SD) p-value Baseline (SD)
T. Choles 183.0 (10.6) 176.8 (10.0) 0.25 182.0 (7.8)
HDL 46.0 (2.6) 46.3 (2.6) 0.73 47.6 (2.5)
LDL 102.7 (9.1) 98.4 (8.8) 0.53 106.3 (7.3)
TG* 172.9 (25.1) 158.4 (18.8) 0.38 140.2 (10.1)
CRP 2.36 (0.57) 3.72 (1.00) 0.41 3.03 (0.85)
Leptin* 53.5 (6.8) 44.2 (5.3) 0.38 33.3 (6.2)
Insulin 20.2 (3.2) 20.6 (3.3) 0.83 15.4 (2.0)
Glucose 130.0 (9.8) 130.7 (11.2) 0.93 128.9 (10.8)
HOMA-IR* 5.97 (0.83) 6.39 (1.08) 0.6 4.77 (0.84)
HbAlc 7.15 (0.34) 7.07 (0.35) 0.41 6.81 (0.30)
*p-values derived from log transformed data.
Data are the mean (SD) at baseline and after oil supplementation (combined 4- and
statistical significance are shown by a bolded p-value.A major consideration in this type of study is the choice
of placebo. For example, in a recent meta-analysis of ran-
domized controlled trials [37], placebos included CO, olive
oil, palm oil, soybean oil and rapeseed oil. Each of these
provides a challenge as a placebo because they containfile and biomarkers
BO FO
Post-oil (SD) p-value Baseline (SD) Post-oil (SD) p-value
171.9 (7.2) 0.05 180.6 (8.3) 183.0 (10.1) 0.71
48.6 (2.9) 0.29 40.7 (2.8) 43.6 (2.8) 0.01
96.8 (6.6) 0.04 102.6 (8.3) 107.9 (9.0) 0.32
132.0 (10.8) 0.14 187.2 (22.0) 156.8 (14.7) 0.03
3.06 (0.86) 0.99 6.08 (3.19) 3.59 (1.03) 0.19
33.9 (7.4) 0.82 45.1 (11.0) 40.6 (7.2) 0.37
17.7 (2.6) 0.24 19.1 (4.5) 24.6 (6.8) 0.02
125.9 (7.3) 0.93 133.5 (16.7) 128.7 (11.1) 0.33
5.76 (1.09) 0.2 8.08 (2.76) 9.19 (3.03) 0.14
6.90 (0.27) 0.83 7.42 (0.33) 7.20 (0.32) 0.05
8-week data). Pre – post changes within a supplementation arm that reached
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leic acid (18:2n-6), oleic acid (18:1n-9) and erucic acid
(22:1n-9), which may have their own biological effects.
In the current study, we chose a parallel design to
compare supplementation with three separate oils, CO,
a BO combination or FO. While not a true placebo, we
expected that CO would not impact biomarkers associated
with T2D as it contains the most abundant PUFA (linoleic
acid) found in the modern Western diet (MWD). Linoleic
acid comprises 6 to 8% of energy in the MWD, so addition
of ~4 g adds only marginally to daily LA exposure [38]. As
expected, CO only marginally increased serum levels of
LA and had no effect on levels of any other PUFAs. Like-
wise, CO had no impact on any of the biomarkers associ-
ated with T2D.
The key novel aspect of this study was the use of a BO
combination composed of borage and echium oils, which
contain both n-3 and n-6 PUFAs, and have been shown to
influence disease biomarkers and clinical symptoms in
several studies. For example, GLA-containing oils have
been demonstrated to reduce rheumatoid arthritis disease
activity and alter cytokine secretion and eicosanoid gener-
ation in numerous studies [22-25]. Echium oil, which con-
tains SDA, has been shown to elevate n-3 LcPUFA levels,
particularly EPA and reduce triglycerides in hypertrigly-
ceridemic patients [39]. Echuim oil also has been shown
to improve insulin sensitivity in non-human primates, and
SDA has been proposed for the management and treat-
ment of diabetes [28,40]. Dietary consumption of milled
flaxseed or flaxseed oil (containing ALA) was shown to
have no impact on glycemic control [41]. We have
recently determined the optimal ratios [27] of these two
botanical oils that will elevate levels of anti-inflammatory
PUFAs and reduce eicosanoids in asthmatic patients.
However, we are not aware of randomized clinical trials
that have specifically examined the impact of these botan-
ical oils on T2D.
This BO combination induced increases in serum
levels of several n-6 PUFAs including GLA and DGLA.
As expected, there was also a small increase in circulat-
ing levels of ARA. This combination also elevated levels
of n-3 PUFAs including ALA, SDA, EPA and DPA. With
regard to biomarkers associated with T2D, the BO com-
bination significantly impacted the lipid profile by redu-
cing total and LDL cholesterol. There were also trends
toward lower triglycerides and higher HDL cholesterol.
There were no changes in glucose, CRP or leptin levels.
The most consistent effect of FO on disease biomarkers
is its ability to lower triglycerides, especially in hypertri-
glyceridemic patients. N-3 LcPUFAs also have general
anti-inflammatory properties. For example, DHA itself
is known to directly inhibit NF-κB activation [42,43], and
DHA (and EPA)-derived resolvins and protectins [21,44,45]
are proposed to dampen and resolve inflammatoryresponses. EPA also has important anti-inflammatory
properties and effectively competes with AA for enzymes
that participate in eicosanoid biosynthesis [46-48]. N-3
LcPUFAs also increase levels of n-3 derived endocannabi-
noids with potential anti-inflammatory effects [49]. As
expected, supplementation with FO caused a marked
elevation in serum n-3 LcPUFAs including EPA, DPA
and DHA. Fish oil also markedly reduced triglycerides
and induced an increase in HDL-cholesterol. Interestingly,
hemoglobin A1c was significantly reduced in the FO arm,
and there was a trend toward lower circulating glucose
and CRP levels. However, it is important to point out that
the FO arm began the study with higher baseline levels of
CRP. There was also a small, but significant increase in
insulin levels with FO supplementation. The explanation
for this unexpected increase is unclear at this time.
There are a number of potential limitations to our
study which include the length of the study (8 weeks),
the placebo oil, the lack of control for background PUFA
exposure, and the use of a patient population that
contained both individuals with early-stage T2D and
metabolic syndrome. We have addressed the placebo
issue above and feel that CO is justified here as it adds
only marginally to the PUFAs that are already being
consumed in the background MWD. With regard to
study length, serum PUFA levels reached equilibrium
within 4 weeks of providing the supplements, and so
there had been constant PUFA exposure to the subjects
for at least 4 weeks. However, there have been some small
reported effects of treatment duration on plasma lipids
and lipoproteins, especially in studies of less than 3 months
[49]. Additionally, some biomarkers such as hemoglobin
A1c reflect cumulative changes that occur over several
weeks to months, so treatment duration can be particu-
larly important for these biomarkers. That being said,
there was a significant decrease in hemoglobin A1c during
the 8-week trial in the FO arm. It would be interesting to
determine if FO further reduced this important biomarker
during a longer period intervention. Another potential
limitation of the study was the gastrointestinal symptoms
observed in a few of the participants. However, these
symptoms tended to be transient and only one patient
chose to withdraw from the study because of this side ef-
fect. In terms of background PUFA exposure, the patients
were provided a list of foods and supplements that con-
tained high quantities of PUFAs not normally found in
their diets and were told not to eat these foods or supple-
ments during the study. Perhaps the best evidence for
consistent PUFA exposure (between subjects) is the fact
that aside from the PUFAs and their metabolites in sup-
plements given, there was little individual variation in
serum PUFAs from baseline levels (Table 2 and Figure 3).
With regard to the patient population, there were no
significant differences between the groups with regard to
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groups have similar measures of glucose regulation in-
cluding circulating glucose levels and hemoglobin A1c
values. With these limitations taken into consideration,
this study suggests that a BO combination, as well as FO,
may have the capacity to reduce some risk factors associ-
ated with T2D/metabolic syndrome. Future studies utiliz-
ing longer interventions and larger sample sizes will be
necessary to better understand the degree to which these
supplements can impact dyslipidemia, inflammation and
glucose homeostasis in patients with T2D and metabolic
syndrome.
Conclusion
This study has shown that short-term dietary supple-
mentation with BO and FO has the capacity to improve
disease biomarkers associated with T2D/metabolic
syndrome. These results together with our previous
observations that similar botanical oil combinations
reduce eicosanoid generation in asthmatic patients [27]
suggest that certain botanical oil combinations may have




Encapsulated oils obtained from echium seeds (Echium
plantagineum L.), borage seeds (Borago officinalis L.),
corn seeds (Zea mays L.) and fish (Brevoortia tyrannis
Latrobe) were a generous gift from Croda Europe Ltd
(Leek, Staffordshire, UK). The oils were authenticated by
the Wake Forest School of Medicine Center for Botanical
Lipids and Inflammatory Disease Prevention. Table 3
shows the fatty acid composition of each oil. Figure 1 illus-
trates the primary points where PUFAs in these oil supple-
ments enter the human PUFA biosynthetic pathway.
Subjects
The study was reviewed and approved by the Wake Forest
University Health Sciences Institutional Review Board, a
part of the Human Research Protection Program (HRPP).
The inclusion criteria were: Adults aged ≥ 21 year, with
either diabetes or metabolic syndrome. The study uti-
lized The National Cholesterol Education Program Adult
Treatment Panel (NCEP ATP) III definition of Metabolic
syndrome requiring someone to have three or more of the
five following risk factors: 1) central obesity as measured
by waist circumference (men ≥ 40 inches; women ≥ 35
inches; 2) fasting blood triglycerides ≥ 150 mg/dL (or taking
triglyceride-lowering medications); 3) low fasting blood
HDL (men ≤ 40 mg/dL, women ≤ 50 mg/dL; 4) elevated
blood pressure (≥130/85mmHG, or on blood pressure
lowering medication); and 5) fasting glucose ≥ 100 mg/dL
(or diabetes treatment) [50]. T2D was confirmed bydocumented history of treatment. Participant exclusion
criteria included: 1) current use of anti-inflammatory
drugs including NSAIDs, oral/IV steroids, other injection
anti-inflammatory drugs (for rheumatoid arthritis), aspirin
(>100 mg/day), leukotriene receptor antagonists, niacin,
fibrates or fish oil; 2) blood pressure > 170/100 mm/Hg; 3)
HbA1c > 10%; 3) fasting blood triglycerides > 500 mg/dL;
4) myocardial infarction, vascular surgery, or stroke in the
past year; 5) any stage II/III/IV heart failure, prior chole-
cystectomy, or end stage renal disease ; 6) BMI <23 or >
45; 7) pregnancy; 8) alcohol use > 14 drinks per week; 9)
self-reported current tobacco smoking or other illicit drug
use; and 10) intolerance or allergy to fish oil.
Eighty (80) participants with either early-stage T2D or
metabolic syndrome were recruited for the 8-week study
(Figure 2). Early-stage T2D was defined as subjects with
a diagnosis of T2D without evidence of end-stage organ
damage secondary to their disease, including end-stage
renal disease. Written informed consent was obtained
from all subjects prior to enrollment. Nine of the initially
recruited subjects were disqualified from the study be-
cause they failed to meet inclusion criteria.
Study design
Consented participants were randomly assigned to one
of three supplementation arms (Figure 2). Subjects in
each arm consumed encapsulated oils along with their
normal diets. The oils were: corn oil (CO);botanical oil
(BO; combination of echium and borage oils); and fish
oil (FO). These supplements were consumed with meals
twice a day. The PUFA dosage in each oil arm is shown
in Table 3 (right panel) and was achieved with the con-
sumption of 9 daily CO capsules, 10 daily BO capsules
(7 echium and 3 borage) or 9 daily FO capsules. The
appearance of soft gelatin oil capsules was identical and
participants were blind to the arm to which they were
randomized. This was a single-blind study due to the
differing number of daily capsules that were administered
to each group. The ‘typical’ western diet provides very
small quantities of gamma-linolenic acid (GLA) and stear-
idonic acid (SDA), limiting the ability to detect these
PUFAs in circulating or cellular lipids. GLA and SDA are
only typically observed when individuals are consuming
GLA- or SDA-containing supplements such as borage,
evening primrose, black currant, or echium oils. The use
of any of these oils was an exclusion criterion of the study.
Participants were advised to minimize fish intake
during the supplementation period, to refrain from self-
medication with anti-inflammatory drugs and to inform
the study staff about any health concerns during the study.
The study was conducted in the Wake Forest University
Health Sciences Clinical Research Unit where biospeci-
mens (fasting blood and urine collected between 7:00 a.m.
and 10:00 a.m.), vital signs (blood pressure and resting
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hip circumference, height, body mass index [BMI] and
body fat) were measured at baseline, 4- and 8-weeks after
beginning supplementation.
Subjects reported any change in their medical condition
at each study visit and used diary cards to record all med-
ical symptoms and to log intake of study oils. Compliance
was monitored by multiple mechanism including serum
fatty acid profiles at 4- and 8-weeks, medication diaries
and counts of returned capsules during the study. Capsule
return counts indicated an average of 95% of capsules
were taken (range = 76% - 100%).
The most common adverse events associated with
taking PUFA-based dietary supplements were gastro-
intestinal symptoms reported as gas, constipation, loose
stools, and/or abdominal pain or discomfort. These
symptoms typically were mild, transient, occurred in the
first few days of the study and were resolved within 2 to
3 days of first consuming the supplements.
A total of twelve (12) participants did not complete
the study. One person dropped out of the study for
abdominal discomfort and another from difficulty swal-
lowing the capsules. Five participants withdrew from the
study to resume taking non-steroidal anti-inflammatory
drugs (NSAIDs); this was the most common reason for
withdrawal. One participant withdrew due to an unrelated
surgery and another needed to begin taking a new medica-
tion. One subject was removed from the study when their
platelet count moved out of the normal range. Two sub-
jects removed themselves from the study before 4-and
8-week samples could be acquired (Figure 2). There
were no significant changes in vital signs in any study
subjects during the study.
Biochemical measurements
Measurements from blood samples included fasting
glucose, insulin, high-sensitivity C-reactive protein (hs-
CRP), leptin, hemoglobin A1c, CBC with differential/
platelet, and serum lipids (total cholesterol, triglycerides,
HDL-, VLDL- and LDL-cholesterol). Creatinine levels
were obtained from urine samples. These endpoints
were analyzed by a qualified clinical laboratory (Lab
Corp, Burlington, NC).
Fatty acid analysis
Serum was isolated from fasting whole blood and fatty
acid methyl esters (FAME) were prepared [51] after
saponification of duplicate samples (100 μl) in the pres-
ence of an internal standard (triheptadecanoin: Nuchek
Prep, Elysian, MN, USA) as previously described [52]. A
panel of 28 fatty acids was quantified by gas chromatog-
raphy with flame ionization detection and individual fatty
acids are expressed as percent of total fatty acids in each
sample.The fatty acid composition of the oil supplements
(Table 3) was determined in aliquots of oil diluted in
hexane and processed as described above. Individual
fatty acids were expressed as percent of total fatty acids
and as grams fatty acid/grams oil in order to calculate
the fatty acid doses for each intervention arm.
Statistical analysis
Baseline subject characteristics were summarized by
the number (percent) for categorical data and mean
(standard deviation) for continuous measures. Compari-
son of changes from baseline to the post supplemental
period was performed by paired t-tests comparing the
baseline value with the mean of the 4- and 8-week values.
P values for the comparison of the cytokine levels were
made using a logarithmic transformation because these
values were skewed to the right and the transformation
normalized the values and stabilized the variances. Mea-
sures of fatty acids were not normalized with a logarithmic
transformation; therefore, non-parametric methods were
used for hypothesis tests. The change in the distribution
of fatty acid levels from pre- to post-treatment was com-
pared using the sign-rank test and comparison of changes
between oil supplementation arms were made by the
Wilcoxon rank sum test.
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